Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1231 • ACR Convergence 2020
Radiographic Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib as Monotherapy or in Combination with Methotrexate: Results at 2 Years
Charles Peterfy¹, Vibeke Strand², Mark Genovese³, Alan Friedman⁴, Jeffrey Enejosa⁴, Stephen Hall⁵, Eduardo Mysler⁶, Patrick Durez⁷, Xenofon Baraliakos⁸, Tim Shaw⁴, Yanna Song⁹, Yihan Li⁴ and In-Ho Song⁴, ¹Spire Sciences, Inc., Boca Raton, FL, ²Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ³Stanford University Medical Center, Palo Alto, CA, ⁴AbbVie Inc., North Chicago, IL, ⁵Cabrini Medical Centre, Monash University and Emeritus Research, Malvern, Victoria, Australia, ⁶Organización Medica de Investigación, Buenos Aires, Argentina, ⁷Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium, ⁸Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, ⁹AbbVie Inc., North Chicago,, IL
Background/Purpose: For patients with rheumatoid arthritis (RA), long‑term prevention of structural joint damage is a key treatment goal.1 In the SELECT-EARLY and SELECT-COMPARE trials, upadacitinib…
Abstract Number: 1412 • ACR Convergence 2020
A T Cell Intrinsic Role for Nod2 in Suppression of Th17-Mediated Experimental Arthritis and Uveitis: Implications for Blau Syndrome
Ruth Napier¹, Ellen Lee¹, Emily Vance¹, Sydney Lashley², Luke Uebelhoer³, Christina Lancioni³, Richard Vehe⁴, Bryce Binstadt⁴, Rachel Caspi⁵ and Holly Rosenzweig¹, ¹Oregon Health & Science University and VA Portland Health Care System, Portland, OR, ²VA Portland Health Care System, Portland, OR, ³Oregon Health & Science University, Portland, ⁴University of Minnesota, Minneapolis, MN, ⁵NIH, Bethesda, MD
Background/Purpose: Mutations in nucleotide-binding oligomerization domain-containing protein 2 (NOD2) cause Blau syndrome, an inflammatory disorder characterized by uveitis, dermatitis, and polyarthritis. The antimicrobial functions of NOD2 are…
Abstract Number: 1529 • ACR Convergence 2020
Differentially Expressed Chemokines and Cytokines in Peripheral Blood Mononuclear Cells (PBMCs) of Rheumatoid Arthritis (RA) Patients
Noha Elemam¹, Mahmood Hachim², Suad Hannawi³ and Azzam Maghazachi⁴, ¹University of Sharjah, Sharjah, United Arab Emirates, ²Mohammed Bin Rashid University Of Medicine and Health Sciences, Dubai, ³Ministry of Health and Prevention, Dubai, United Arab Emirates, ⁴University of Sharjah, Sharjah
Background/Purpose: Rheumatoid arthritis (RA) is the most prevalent autoimmune disease, where various immune cells are associated such as monocytes, natural killer (NK) cells, B cells,…
Abstract Number: 1587 • ACR Convergence 2020
Improving Cardiovascular Risk Assessment in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus in an Internal Medicine Resident Clinic: A Quality Improvement Initiative
Anna Falls¹, Peta-Gay Ricketts¹, Kelli Fox¹, Teresa George¹ and Chelsey Petz¹, ¹OhioHealth Riverside Methodist Hospital, Columbus, OH
Background/Purpose: Cardiovascular disease is one of the leading causes of death in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients. Its risk in RA…
Abstract Number: 1716 • ACR Convergence 2020
Predictors of Unacceptable Pain and Unacceptable Pain with Low Inflammation in Early Rheumatoid Arthritis
Anna Eberhard¹, Tor Olofsson², Stefan Bergman³, Thomas Mandl⁴ and Carl Turesson⁵, ¹Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Department of Clinical Sciences Lund, Rheumatology, Lund University, Sweden. Department of Rheumatology, Skåne University Hospital, Lund, Sweden., Lund, Sweden, ³Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden, ⁴Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, ⁵Rheumatology, Department of Clinical Sciences Malmö, Lund University, Department of Rheumatology, Skåne University Hospital, Malmö, Sweden., Malmö, Sweden
Background/Purpose: Pain is a common and debilitating symptom in patients with rheumatoid arthritis (RA). In early RA it is usually due to ongoing inflammation and…
Abstract Number: 1732 • ACR Convergence 2020
Machine Learning Coupled with Patient Reported Outcome Data to Classify & Predict RA Disease Activity
Jeffrey R Curtis¹, Fenglong Xie², Shelly Kafka³ and Shawn Black³, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Janssen Scientific Affairs, LLC, Horsham, PA
Background/Purpose: Patient reported outcome (PRO) data have assumed increasing importance in the care of rheumatoid arthritis (RA) patients. However, physician-derived disease activity measures such as…
Abstract Number: 1749 • ACR Convergence 2020
Efficacy of Filgotinib in Patients with Rheumatoid Arthritis with Poor Prognostic Factors: Post Hoc Analysis
Daniel Aletaha¹, Rene Westhovens², Cecile Gaujoux-Viala³, Giovanni Adami⁴, Alan Matsumoto⁵, Paul Bird⁶, Osvaldo Daniel Messina⁷, Maya Buch⁸, Beatrix Bartok⁹, Zhaoyu Yin⁹, Ying Guo¹⁰, Thijs Hendrikx¹¹ and Gerd Burmester¹², ¹Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, ²University Hospitals Leuven, Belgium, Leuven, Belgium, ³Department of Rheumatology, CHU Nîmes, University of Montpellier-Nîmes, France, EA2415, University of Montpellier, Montpellier, France, Nîmes, France, ⁴University of Verona, Verona, Italy, ⁵Arthritis and Rheumatism Assoc, Wheaton, MD, ⁶University New South Wales, Sydney, Australia, ⁷IRO Medical Ctr & Cosme Argerich Hospital, Buenos Aires, Argentina, ⁸Centre of Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, United Kingdom, ⁹Gilead Sciences, Inc., Foster City, CA, ¹⁰Gilead Sciences, Inc., Foster City, ¹¹Galapagos BV, Leiden, Netherlands, ¹²Charité University Hospital Berlin, Berlin, Germany
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) with poor prognostic factors (PPF) are at risk for RA progression if disease activity is not rapidly controlled.…
Abstract Number: 1773 • ACR Convergence 2020
Worse Maternal and Fetal Outcomes Among Hospitalized U.S. Pregnant Women with Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA)
Christine Anastasiou¹, Laura Trupin¹, Patricia Katz², Zara Izadi³, Milena Gianfrancesco¹, Gabriela Schmajuk⁴ and Jinoos Yazdany⁵, ¹University of California, San Francisco, San Francisco, CA, ²University of California, San Francisco, Novato, CA, ³University of California San Francisco, San Francisco, CA, ⁴University of California, San Francisco, Atherton, CA, ⁵UCSF, San Francisco, CA
Background/Purpose: Prior studies suggest women with SLE and RA may have higher age-adjusted risk of adverse pregnancy outcomes. We evaluated maternal and fetal complications and…
Abstract Number: 1981 • ACR Convergence 2020
Patients with Inflammatory Arthritis Who Are More Adherent to Treatment Do Not Perform More Physical Activity Collected by Smartphone Apps: A Cross-sectional Study of 101 Patients, the ImBAIA Study
Thomas Davergne¹, Rawdha Tekaya², Camille Deprouw³, Anne Tournadre⁴, Stéphane Mitrovic⁵, Adeline Ruyssen-Witrand⁶, Christophe Hudry⁷, Sabrina Dadoun⁸, Jérôme Avouac⁹, Kate Betteridge¹⁰, Bruno Fautrel¹¹ and Laure Gossec¹², ¹Sorbonne University, INSERM, IPLES, Paris, France, ²Hôpital Charles Nicolle, Rheumatology department, Tunis, Tunisia, Tunis, Tunisia, ³1. AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Paris, 75012, France, Paris, France, ⁴CHU Gabriel Montpied, Clermont-Ferrand, ⁵Institut Mutualiste Montsouris, Rheumatology department, Paris, France, Paris, Ile-de-France, France, ⁶Hôpital Purpan, CHU Toulouse, Toulouse, France, ⁷CeSOA, MGEN, Paris, France, Paris, Ile-de-France, France, ⁸Medical centre, Paris, France, paris, Ile-de-France, France, ⁹Cochin hospital, Rheumatology department, Paris, France, Paris, Ile-de-France, France, ¹⁰Patient research partner, UK, london, England, United Kingdom, ¹¹Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, ¹²Sorbonne University, INSERM; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France
Background/Purpose: Adherence to both medications and physical activity is insufficient in patients with inflammatory arthritis (IA), such as spondyloarthritis (axSpA), rheumatoid arthritis (RA) or psoriatic…
Abstract Number: 2009 • ACR Convergence 2020
Treat-to Target for Early RA Patients in Usual Clinical Practice, a Randomized Study with a Favorable Effect of a Second Oral Pulse of Prednisolone. the Amsterdam COBRA Treat-to-target Study
Linda Hartman¹, Linda Rasch², Samina Turk³, Marieke ter Wee¹, Pit Kerstens⁴, Conny van der Laken⁵, Mike Nurmohamed⁶, Dirkjan van Schaardenburg⁷, Lilian van Tuyl⁸, Alexandre Voskuyl¹, Maarten Boers⁷ and Willem Lems¹, ¹Amsterdam Rheumatology and Immunology Center, location Amsterdam UMC, VUmc, Amsterdam, Netherlands, ²Amsterdam Rheumatology and Immunology Center, location Amsterdam UMC, VUmc, Amsterdam, ³Amsterdam Rheumatology and Immunology Center, location Reade, Amsterdam, Netherlands, ⁴Westfriesgasthuis, Hoorn, Netherlands, ⁵Amsterdam Rheumatology and immunology Center, location Amsterdam UMC, VU medical center, Amsterdam, Netherlands, ⁶Amsterdam Rheumatology and immunology Center, location Reade and Amsterdam UMC, VU medical center, Amsterdam, Netherlands, ⁷Amsterdam Rheumatology and immunology Center | Reade and Amsterdam UMC, Amsterdam, Netherlands, ⁸Nivel, Utrecht, Netherlands
Background/Purpose: EULAR guidelines advise to start with methotrexate (MTX) for early rheumatoid arthritis (RA), either alone or combined with prednisolone. Since this strategy is not…
Abstract Number: 0041 • ACR Convergence 2020
Association of the RPA3-UMAD1 Locus with Interstitial Lung Diseases Complicated with Rheumatoid Arthritis in Japanese
Yuya Shirai¹, Suguru Honda², Katsunori Ikari³, Masahiro Kanai⁴, Yoshito Takeda⁵, Yoichiro Kamatani⁶, Takayuki Morisaki⁷, Eiichi Tanaka⁸, Atsushi Kumanogoh⁹, Masayoshi Harigai¹⁰ and Yukinori Okada¹¹, ¹Osaka university, Suita, Japan, ²Tokyo Women's Medical University, Tokyo, Japan, ³Tokyo Women's Medical University, Shinjuku, Japan, ⁴Harvard Medical School, Boston, ⁵Osaka university, Osaka, ⁶Graduate School of Frontier Sciences, the University of Tokyo, Tokyo, Japan, ⁷The institute of Medical Science, the University of Tokyo, Tokyo, Japan, ⁸Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ⁹Osaka university, Osaka, Japan, ¹⁰Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ¹¹Osaka University Graduate School of Medicine, Osaka, Japan
Background/Purpose: The genetic background of rheumatoid arthritis-interstitial lung disease (RA-ILD) has been evaluated in Europeans, but little knowledge has been obtained in non-Europeans. In particular,…
Abstract Number: 0108 • ACR Convergence 2020
The Relationship Between Body Fat Percentage and Bone Mineral Density in Rheumatoid Arthritis Patients
Anastasia- Vasiliki Madenidou¹ and Marwan Bukhari², ¹Rheumatology Department, University Hospitals of Morecambe Bay NHS Trust, Barrow-in-Furness, United Kingdom, ²Rheumatology Department, University Hospitals of Morecambe Bay NHS Trust, Lancaster, United Kingdom
Background/Purpose: Currently, Dual-Energy X-ray Absorptiometry (DEXA) scans are used to determine fracture risk by calculating Bone Mineral Density (BMD). It is well established that body…
Abstract Number: 0153 • ACR Convergence 2020
Counseling on Safe Driving Strategies in Patients with Osteoarthritis and Rheumatoid Arthritis
Anna Falls¹, Peta-Gay Ricketts¹, John Elliott¹ and Kim Jordan¹, ¹OhioHealth Riverside Methodist Hospital, Columbus, OH
Background/Purpose: Osteoarthritis (OA) and rheumatoid arthritis (RA) cause functional impairments that impact daily life activities, including automobile driving. Radiographic presence of OA on knee and…
Abstract Number: 0188 • ACR Convergence 2020
The Risk of Fractures in a Community-based Cohort of Patients with Rheumatoid Arthritis Compared with the Background Population
Lisa Theander¹, Jan Åke Nilsson², Minna Willim³, Lennart T.H. Jacobsson⁴ and Carl Turesson⁵, ¹Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Sweden, Malmö, Sweden, ²Rheumatology, Department of Clinical Sciences, Malmö, Lund University. Department of Rheumatology, Skåne University Hospital, Malmö and Lund, Sweden, Malmö, Sweden, ³Rheumatology, Department of Clinical Sciences, Lund, Lund University. Department of Rheumatology, Skåne University Hospital, Malmö and Lund, Sweden, Malmö, Sweden, ⁴Rheumatology, Department of Clinical Sciences, Malmö, Lund University. Department of Rheumatology and inflammation research, Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden., Gothenburg, Sweden, ⁵Rheumatology, Department of Clinical Sciences Malmö, Lund University, Department of Rheumatology, Skåne University Hospital, Malmö, Sweden., Malmö, Sweden
Background/Purpose: Rheumatoid Arthritis (RA) has been associated with increased risk of osteoporosis and fractures. We have recently presented results on DXA measurements over 10 years…
Abstract Number: 0204 • ACR Convergence 2020
Pharmacokinetics and Safety of CT-P17, a Proposed High Concentration (100 mg/mL) Adalimumab Biosimilar, in Comparison with EU-Approved Adalimumab and US-Licensed Adalimumab; Results of a Phase 1, Randomized, Double-blind, Three-arm, Single-dose Study in Healthy Subjects
KyungSang Yu¹, InJin Jang¹, HyeongSeok Lim², JangHee Hong³, MinGul Kim⁴, MinKyu Park⁵, Anhye Kim⁶, MinSoo Park⁷, JaeYong Chung⁸, JongLyul Ghim⁹, SeungHwan Lee¹, SeokKyu Yoon², InSun Kwon³, Daniel Furst*¹⁰, Edward C Keystone¹¹, SangJoon Lee¹², SungHyun Kim¹², YunJu Bae¹², JungBin Cha¹³, HyeJin Kang¹³ and Jonathan Kay¹⁴, ¹Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea, ²College of Medicine, University of Ulsan, Asan Medical Center, Seoul, Republic of Korea, ³Chungnam National University Hospital, Daejeon, Republic of Korea, ⁴College of Medicine, Jeonbuk National University, Jeonbuk, Republic of Korea, ⁵Chungbuk National University Hospital, Cheongju, Republic of Korea, ⁶CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea, ⁷Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, ⁸Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ⁹Inje University Busan Paik Hospital, Busan, Republic of Korea, ¹⁰Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²Celltrion, Inc., Incheon, Republic of Korea, ¹³Celltion, Inc., Incheon, Republic of Korea, ¹⁴University of Massachusetts Medical School, Worcester, MA
Background/Purpose: CT-P17 was developed as the first biosimilar of the high concentration (100 mg/mL), citrate-free formulation of reference adalimumab. The purpose of this study was…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].